Cited by 223Alzheimer's disease research and treatmentsParkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Interaction between Aβ Peptide and α Synuclein: Molecular Mechanisms in Overlapping Pathology of Alzheimer’s and Parkinson’s in Dementia with Lewy Body Disease

Mandal, Pravat K., Pettegrew, Jay W., Masliah, Eliezer, Hamilton, Ronald L., Mandal, Ratna·2006·Neurochemical Research

DOI 10.1007/s11064-006-9140-9

Open this paper in CoChat — free account

Abstract

Amyloidogenic proteins (Abeta peptide) in Alzheimer's disease (AD) and alpha-synuclein (alpha-Syn) in Parkinson's disease (PD) are typically soluble monomeric precursors, which undergo remarkable conformational changes and culminate in the form of aggregates in diseased condition. Overlap of clinical and neuropathological features of both AD and PD are observed in dementia with Lewy body (DLB) disease, the second most common form of dementia after AD. The identification of a 35-amino acid fragment of alpha-Syn in the amyloid plaques in DLB brain have raised the possibility that Abeta and alpha-Syn interact with each other. In this report, the molecular interaction of alpha-Syn with Abeta40 and/or Abeta42 are investigated using multidimensional NMR spectroscopy. NMR data in the membrane mimic environment indicate specific sites of interaction between membrane-bound alpha-Syn with Abeta peptide and vice versa. These Abeta-alpha-Syn interactions are demonstrated by reduced amide peak intensity or change in chemical shift of amide proton of the interacting proteins. Based on NMR results, the plausible molecular mechanism of overlapping pathocascade of AD and PD in DLB due to interactions between alpha-Syn and Abeta is described. To the best of our knowledge, it is the first report using multidimensional NMR spectroscopy that elucidates molecular interactions between Abeta and alpha-Syn which may lead to onset of DLB.

Integrity signals

Registry

Crossref · 10.1007/s11064-006-9140-9

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

NMRPipe: A multidimensional spectral processing system based on UNIX pipes
Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,961
α-Synuclein in Lewy bodies
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions
Piotto, M., Saudek, V., & Sklenář, V. (1992) · Journal of Biomolecular NMR · doi:10.1007/bf02192855 · Cited by 3,720
Application of phase sensitive two-dimensional correlated spectroscopy (COSY) for measurements of 1H-1H spin-spin coupling constants in proteins
Marion, D., & Wüthrich, K. (1983) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(83)91093-8 · Cited by 3,160
University of California, San Francisco
(1974) · Medical History · doi:10.1017/s0025727300019682 · Cited by 2,218

Show all 48 references

Sorted by citations

Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Self-citation
The neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329
Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer’s Disease, Parkinson’s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis
Nguyen, P. H., Ramamoorthy, A., Sahoo, B. R., Zheng, J., Faller, P., Straub, J. E., Domínguez, L., Shea, J., Dokholyan, N. V., Simone, A. D., et al. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01122 · Cited by 680
Amyloid oligomers: formation and toxicity of Aβ oligomers
Sakono, M., & Zako, T. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07568.x · Cited by 633
Basic mechanisms of neurodegeneration: a critical update
Jellinger, K. A. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01010.x · Cited by 640
Synergistic Interactions between Aβ, Tau, and α-Synuclein: Acceleration of Neuropathology and Cognitive Decline
Clinton, L. K., Blurton-Jones, M., Myczek, K., Trojanowski, J. Q., & LaFerla, F. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0490-10.2010 · Cited by 576
Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid
Shahnawaz, M., Tokuda, T., Waragai, M., Méndez, N., Ishii, R., Trenkwalder, C., Mollenhauer, B., & Soto, C. A. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.4547 · Cited by 485
Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts
Jellinger, K. A. (2011) · Movement Disorders · doi:10.1002/mds.23795 · Cited by 480
Interactions of pathological proteins in neurodegenerative diseases
Spires‐Jones, T. L., Attems, J., & Thal, D. R. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1709-7 · Cited by 435
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
Shi, M. Y., Bradner, J. M., Hancock, A. M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J. J., Zabetian, C. P., Kim, H. M., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22311 · Cited by 422
α-synuclein in the pathophysiology of Alzheimer’s disease
Twohig, D., & Nielsen, H. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0320-x · Cited by 374
Selective Molecular Alterations in the Autophagy Pathway in Patients with Lewy Body Disease and in Models of α-Synucleinopathy
Crews, L. A., Spencer, B. J., Desplats, P., Patrick, C., Paulino, A., Rockenstein, E. M., Hansen, L. A., Adame, A., Galasko, D. R., & Masliah, E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009313 · Cited by 379
Self-citation
Retracted
Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's Diseases
Tsigelny, I. F., Crews, L., Desplats, P., Shaked, G. M., Sharikov, Y., Mizuno, H., Spencer, B., Rockenstein, E., Trejo, M., Platoshyn, O., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003135 · Cited by 281
Self-citation
Retracted
Recent advances in our understanding of neurodegeneration
Jellinger, K. A. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0240-y · Cited by 274
Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease
Jellinger, K. A., & Attems, J. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0347-5 · Cited by 267
Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
Jellinger, K. A. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1821-9 · Cited by 277
Amyloid-Beta (Aβ) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with Aβ Pathology
Bassil, F., Brown, H. J., Pattabhiraman, S., Iwasyk, J. E., Maghames, C. M., Meymand, E. S., Cox, T. O., Riddle, D. M., Zhang, B., Trojanowski, J. Q., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.10.010 · Cited by 246
A critical evaluation of current staging of α-synuclein pathology in Lewy body disorders
Jellinger, K. A. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.07.006 · Cited by 247
A critical reappraisal of current staging of Lewy-related pathology in human brain
Jellinger, K. A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0406-y · Cited by 240
Cross-Seeding of Misfolded Proteins: Implications for Etiology and Pathogenesis of Protein Misfolding Diseases
Morales, R., Moreno‐González, I., & Soto, C. A. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003537 · Cited by 225
Cross‐seeding effects of amyloid β‐protein and α‐synuclein
Ono, K., Takahashi, R., Ikeda, T., & Yamada, M. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07847.x · Cited by 222
Neuropathology of dementia in patients with Parkinson’s disease: a systematic review of autopsy studies
Smith, C., Malek, N., Grosset, K. A., Cullen, B., Gentleman, S., & Grosset, D. G. (2019) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-321111 · Cited by 213
Confluence of α-Synuclein, Tau, and β-Amyloid Pathologies in Dementia With Lewy Bodies
Colom‐Cadena, M., Gelpí, E., Charif, S., Belbin, O., Blesa, R., Martí, M. J., Clarimón, J., & Lleó, A. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000018 · Cited by 188
Efficient RT-QuIC seeding activity for α-synuclein in olfactory mucosa samples of patients with Parkinson’s disease and multiple system atrophy
Luca, C. M. G. D., Elia, A. E., Portaleone, S. M., Cazzaniga, F. A., Rossi, M., Bistaffa, E., Cecco, E. D., Narkiewicz, J., Salzano, G., Carletta, O., et al. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0164-x · Cited by 190
Simulation Studies of Amyloidogenic Polypeptides and Their Aggregates
Ilie, I. M., & Caflisch, A. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00731 · Cited by 181
Membrane lipid rafts and neurobiology: age‐related changes in membrane lipids and loss of neuronal function
Egawa, J., Pearn, M. L., Lemkuil, B. P., Patel, P. M., & Head, B. P. (2015) · The Journal of Physiology · doi:10.1113/jp270590 · Cited by 184
Cortical α-synuclein load is associated with amyloid-β plaque burden in a subset of Parkinson’s disease patients
Lashley, T., Holton, J. L., Gray, E., Kirkham, K., O’Sullivan, S. S., Hilbig, A., Wood, N. W., Lees, A. J., & Révész, T. (2008) · Acta Neuropathologica · doi:10.1007/s00401-007-0336-0 · Cited by 172
Interactions of Pathological Hallmark Proteins
Oláh, J., Vincze, O., Virók, D., Simon, D., Bozsó, Z., Tőkési, N., Horváth, I., Hlavanda, E., Kovács, J., Magyar, A., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.243907 · Cited by 137
Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains
Walker, D. G., Lue, L., Adler, C. H., Shill, H. A., Caviness, J. N., Sabbagh, M. N., Akiyama, H., Serrano, G. E., Sue, L. I., & Beach, T. G. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.11.020 · Cited by 153
Biophysical processes underlying cross-seeding in amyloid aggregation and implications in amyloid pathology
Ivanova, M. I., Lin, Y., Lee, Y., Zheng, J., & Ramamoorthy, A. (2020) · Biophysical Chemistry · doi:10.1016/j.bpc.2020.106507 · Cited by 157
Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features
Goldman, J. G., Andrews, H., Amara, A. W., Naito, A., Alcalay, R. N., Shaw, L. M. J., Taylor, P., Xie, T., Tuite, P., Henchcliffe, C., et al. (2017) · Movement Disorders · doi:10.1002/mds.27232 · Cited by 149
Cross-interactions between the Alzheimer Disease Amyloid-β Peptide and Other Amyloid Proteins: A Further Aspect of the Amyloid Cascade Hypothesis
Luo, J., Wärmländer, S. K. T. S., Gräslund, A., & Abrahams, J. P. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.714576 · Cited by 142
Neuropathological Aspects of Alzheimer Disease, Parkinson Disease and Frontotemporal Dementia
Jellinger, K. A. (2008) · Neurodegenerative Diseases · doi:10.1159/000113679 · Cited by 139
Examining the mechanisms that link β-amyloid and α-synuclein pathologies
Marsh, S. E., & Blurton-Jones, M. M. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt109 · Cited by 140
Fundamentals of cross-seeding of amyloid proteins: an introduction
Ren, B., Zhang, Y., Zhang, M., Liu, Y., Zhang, D., Gong, X., Feng, Z., Tang, J., Chang, Y., & Zheng, J. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb01871a · Cited by 139
The Cerebrospinal Fluid Amyloid β42/40 Ratio in the Differentiation of Alzheimers Disease from Non-Alzheimers Dementia
Spies, P. E., Slats, D., Sjögren, M. J. C., Kremer, B. P. H., Verhey, F. R. J., Rikkert, M. G. M. O., & Verbeek, M. M. (2010) · Current Alzheimer Research · doi:10.2174/156720510791383796 · Cited by 140
Enteric alpha‐synuclein expression is increased in Parkinson's disease but not Alzheimer's disease
Gold, A., Turkalp, Z. T., & Munoz, D. G. (2013) · Movement Disorders · doi:10.1002/mds.25298 · Cited by 132
Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders
Valera, E., Spencer, B. J., & Masliah, E. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0397-z · Cited by 135
Self-citation
Interaction between pathogenic proteins in neurodegenerative disorders
Jellinger, K. A. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01507.x · Cited by 132
Neuropathology of dementia in a large cohort of patients with Parkinson's disease
Horvath, J. E., Herrmann, F. R., Burkhard, P. R., Bouras, C., & Kövari, E. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.05.010 · Cited by 124
Complement 3 and Factor H in Human Cerebrospinal Fluid in Parkinson's Disease, Alzheimer's Disease, and Multiple-System Atrophy
Wang, Y., Hancock, A. M., Bradner, J. M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D. R., Jankovic, J. J., Zabetian, C. P., Kim, H. M., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.01.006 · Cited by 121
Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson’s disease
Barreto, G. E., Iarkov, A., & Echeverrı́a, V. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00340 · Cited by 119
Amyloid Cross-Seeding: Mechanism, Implication, and Inhibition
Subedi, S., Sasidharan, S., Nag, N., Saudagar, P., & Tripathi, T. (2022) · Molecules · doi:10.3390/molecules27061776 · Cited by 115
Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development
Mueed, Z., Tandon, P., Maurya, S. K., Deval, R., Kamal, M. A., & Poddar, N. K. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01017 · Cited by 111
α-Synuclein modulates tau spreading in mouse brains
Bassil, F., Meymand, E. S., Brown, H. J., Xu, H. W., Cox, T. O., Pattabhiraman, S., Maghames, C. M., Wu, Q., Zhang, B., Trojanowski, J. Q., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20192193 · Cited by 109
Structural and Functional Insights into α-Synuclein Fibril Polymorphism
Mehra, S., Gadhe, L. G., Bera, R., Sawner, A. S., & Maji, S. K. (2021) · Biomolecules · doi:10.3390/biom11101419 · Cited by 111
In Vitro and Mechanistic Studies of an Antiamyloidogenic Self-Assembled Cyclic d , l -α-Peptide Architecture
Richman, M., Wilk, S., Chemerovski‐Glikman, M., Wärmländer, S. K. T. S., Wahlström, A., Gräslund, A., & Rahimipour, S. (2013) · Journal of the American Chemical Society · doi:10.1021/ja310064v · Cited by 108
Genome-wide screen identifies curli amyloid fibril as a bacterial component promoting host neurodegeneration
Wang, C., Lau, C. Y., Ma, F., & Zheng, C. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2106504118 · Cited by 106
Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities
Visanji, N. P., Lang, A. E., & Kovács, G. G. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0172-x · Cited by 102
Cross-Seeding Interaction between β-Amyloid and Human Islet Amyloid Polypeptide
Hu, R., Zhang, M., Chen, H., Jiang, B., & Zheng, J. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00192 · Cited by 98
Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson’s disease
Swirski, M., Miners, J. S., de Silva, R., Lashley, T., Ling, H., Holton, J. L., Révész, T., & Love, S. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0077-y · Cited by 98
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
Kwon, S., Iba, M., Kim, C., & Masliah, E. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00853-2 · Cited by 97
Self-citation
Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice
Xu, Y., Xu, K., Sun, Y., Liou, B., Quinn, B., Li, R.-H., Xue, L., Zhang, W., Setchell, K. D. R., Witte, D. P., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu105 · Cited by 88
Role of Synucleins in Alzheimer’s Disease
Crews, L. A., Tsigelny, I. F., Hashimoto, M., & Masliah, E. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9073-6 · Cited by 85
Self-citation
Amylin–Aβ oligomers at atomic resolution using molecular dynamics simulations: a link between Type 2 diabetes and Alzheimer's disease
Baram, M., Atsmon‐Raz, Y., Ma, B., Nussinov, R., & Miller, Y. (2015) · Physical Chemistry Chemical Physics · doi:10.1039/c5cp03338a · Cited by 81
γ-Synuclein: Seeding of α-Synuclein Aggregation and Transmission between Cells
Surgucheva, I. G., Sharov, V. S., & Surguchov, A. P. (2012) · Biochemistry · doi:10.1021/bi300478w · Cited by 86
Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro
Köppen, J., Schulze, A., Machner, L., Wermann, M., Eichentopf, R., Guthardt, M., Hähnel, A., Klehm, J., Kriegeskorte, M.-C., Hartlage‐Rübsamen, M., et al. (2020) · Molecules · doi:10.3390/molecules25030580 · Cited by 79
Regional Overlap of Pathologies in Lewy Body Disorders
Colom‐Cadena, M., Grau‐Rivera, O., Planellás, L., Cerquera‐Cleves, C., Morenas‐Rodríguez, E., Helgueta, S., Muñoz, L., Kulisevsky, J., Martı́, M. J., Tolosa, E. S., et al. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx002 · Cited by 80
Alpha-synuclein potentiates Ca2+ influx through voltage-dependent Ca2+ channels
Adamczyk, A., & Strosznajder, J. B. (2006) · Neuroreport · doi:10.1097/wnr.0b013e3280115185 · Cited by 79
Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study
Jellinger, K. A. (2007) · Springer eBooks · doi:10.1007/978-3-211-73574-9_12 · Cited by 77
Significance of Brain Lesions in Parkinson Disease Dementia and Lewy Body Dementia
Jellinger, K. A. (2009) · Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences · doi:10.1159/000197890 · Cited by 74
RETRACTED ARTICLE: Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5 – implications for dementia with Lewy bodies
Overk, C., Cartier, A. E., Shaked, G. M., Rockenstein, E. M., Ubhi, K. K., Spencer, B. J., Price, D. L., Patrick, C., Desplats, P., & Masliah, E. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-18 · Cited by 73
Self-citation
Retracted
Cross Currents in Protein Misfolding Disorders: Interactions and Therapy
Morales, R., Green, K., & Soto, C. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789541998 · Cited by 72
Addenbrooke’s Cognitive Examination III (ACE-III) and mini-ACE for the detection of dementia and mild cognitive impairment
Beishon, L., Batterham, A. P., Quinn, T. J., Nelson, C. P., Panerai, R. B., Robinson, T. G., & Haunton, V. J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013282.pub2 · Cited by 77
Amyloid β-interacting partners in Alzheimer's disease: From accomplices to possible therapeutic targets
Han, S.-H., Park, J.-C., & Mook-Jung, I. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.004 · Cited by 67
Autophagy in Dementias
Kragh, C. L., Ubhi, K. K., Wyss‐Coray, T., & Masliah, E. (2011) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00545.x · Cited by 66
Self-citation
CSF levels of the neuronal injury biomarker visinin‐like protein‐1 in Alzheimer's disease and dementia with Lewy bodies
Luo, X., Hou, L., Shi, H., Zhong, X., Zhang, Y., Zheng, D., Tan, Y., Guoyan, H., Mu, N., Chan, J., et al. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12331 · Cited by 66
Interaction between -Synuclein and Other Proteins in Neurodegenerative Disorders
Jellinger, K. A. (2011) · The Scientific World JOURNAL · doi:10.1100/2011/371893 · Cited by 64
Insights into the Molecular Mechanisms of Alzheimer’s and Parkinson’s Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology
Coskuner‐Weber, O., & Uversky, V. N. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020336 · Cited by 71
A mechanistic survey of Alzheimer's disease
Tang, Y., Zhang, D., Gong, X., & Zheng, J. (2021) · Biophysical Chemistry · doi:10.1016/j.bpc.2021.106735 · Cited by 66
Potential biomarkers and novel pharmacological targets in protein aggregation-related neurodegenerative diseases
Giacomelli, C., Daniele, S., & Martini, C. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.01.017 · Cited by 71
Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk
Kayed, R., Dettmer, U., & Lesné, S. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-201965 · Cited by 63
Non-chaperone Proteins Can Inhibit Aggregation and Cytotoxicity of Alzheimer Amyloid β Peptide
Luo, J., Wärmländer, S. K. T. S., Gräslund, A., & Abrahams, J. P. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.574947 · Cited by 60
A novel PSEN2 mutation associated with a peculiar phenotype
Piscopo, P., Marcon, G., Piras, M. R., Crestini, A., Campeggi, L. M., Deiana, E., Cherchi, R., Tanda, F., Deplano, A., Vanacore, N., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000310643.53587.87 · Cited by 64
Dementia with Lewy Bodies
Ferman, T. J., & Boeve, B. F. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.03.001 · Cited by 68
Protein–protein interactions regulating α-synuclein pathology
Wang, J., Dai, L., Chen, S., Zhang, Z., Fang, X., & Zhang, Z. (2024) · Trends in Neurosciences · doi:10.1016/j.tins.2024.01.002 · Cited by 58
α-synuclein induced synapse damage is enhanced by amyloid-β1-42
Bate, C., Gentleman, S., & Williams, A. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-55 · Cited by 55
α-Synuclein enhances secretion and toxicity of amyloid beta peptides in PC12 cells
Wilkaniec, A., Strosznajder, J. B., & Adamczyk, A. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.08.004 · Cited by 59
α-Synuclein increases β-amyloid secretion by promoting β-/γ-secretase processing of APP
Hall‐Roberts, H., Schneider, B. L., & Brown, D. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171925 · Cited by 55
Non-Amyloid-β Component of Human α-Synuclein Oligomers Induces Formation of New Aβ Oligomers: Insight into the Mechanisms That Link Parkinson’s and Alzheimer’s Diseases
Atsmon‐Raz, Y., & Miller, Y. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00204 · Cited by 56
Disease-modifying drugs and Parkinson's disease
Allain, H., Bentué‐Ferrer, D., & Akwa, Y. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.10.003 · Cited by 52
Piperidine-derived γ-secretase modulators
Hall, A., Elliott, R. L., Giblin, G. M. P., Hussain, I., Musgrave, J., Naylor, A., Sasse, R. Z., & Smith, B. B. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.072 · Cited by 51
Cerebrospinal Fluid Aβ42 Levels: When Physiological Become Pathological State
Martorana, A., Lorenzo, F. D., Belli, L., Sancesario, G., Toniolo, S., Sallustio, F., Sancesario, G. M., & Koch, G. (2015) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12476 · Cited by 51
Exploring pathological link between antimicrobial and amyloid peptides
Tang, Y., Zhang, Y., Zhang, D., Liu, Y., Nussinov, R., & Zheng, J. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00878a · Cited by 53
Disordered Proteins: Biological Membranes as Two-Dimensional Aggregation Matrices
Byström, R., Aisenbrey, C., Borowik, T., Bokvist, M., Lindström, F., Sani, M., Olofsson, A., & Gröbner, G. (2008) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-008-9033-4 · Cited by 50
Cerebral amyloid angiopathy in Lewy body disease
Jellinger, K. A., & Attems, J. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-007-0856-8 · Cited by 50
Self‐Assembled Cyclic d,l ‐α‐Peptides as Generic Conformational Inhibitors of the α‐Synuclein Aggregation and Toxicity: In Vitro and Mechanistic Studies
Chemerovski‐Glikman, M., Rozentur‐Shkop, E., Richman, M., Grupi, A., Getler, A., Cohen, H. Y., Shaked, H., Wallin, C., Wärmländer, S. K. T. S., Haas, E., et al. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201601830 · Cited by 51
Absence of α-synuclein pathology in postencephalitic parkinsonism
Jellinger, K. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0537-9 · Cited by 49
Quantifying Co-Oligomer Formation by α-Synuclein
Iljina, M., Dear, A. J., Garcia, G. A., De, S., Tosatto, L., Flagmeier, P., Whiten, D. R., Michaels, T. C. T., Frenkel, D., Dobson, C. M., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b03575 · Cited by 51
Prodromal Intestinal Events in Alzheimer’s Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition
Pellegrini, C., Daniele, S., Antonioli, L., Benvenuti, L., D’Antongiovanni, V., Piccarducci, R., Pietrobono, D., Citi, V., Piragine, E., Flori, L., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103523 · Cited by 49
Sigma‐2 receptor antagonists rescue neuronal dysfunction induced by Parkinson’s patient brain‐derived α‐synuclein
Limegrover, C. S., Yurko, R., Izzo, N. J., LaBarbera, K. M., Rehak, C., Look, G., Rishton, G., Safferstein, H., & Catalano, S. M. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24782 · Cited by 43
Molecular simulation aspects of amyloid peptides at membrane interface
Liu, Y., Ren, B., Zhang, Y., Sun, Y. P., Chang, Y., Liang, G., Xu, L., & Zheng, J. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.02.004 · Cited by 43
Association of CSF α‐synuclein seed amplification assay positivity with disease progression and cognitive decline: A longitudinal Alzheimer's Disease Neuroimaging Initiative study
Tosun, D., Hausle, Z., Thropp, P., Concha‐Marambio, L., Lamoureux, J., Lebovitz, R. M., Shaw, L. M. J., Singleton, A., Weiner, M. W., Initiative, T. A. D. N., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14276 · Cited by 42
Inhibition of tau-derived hexapeptide aggregation and toxicity by a self-assembled cyclic d , l -α-peptide conformational inhibitor
Belostozky, A., Richman, M., Lisniansky, E., Tovchygrechko, A., Chill, J. H., & Rahimipour, S. (2018) · Chemical Communications · doi:10.1039/c8cc01233d · Cited by 41
HspB2/Myotonic Dystrophy Protein Kinase Binding Protein (MKBP) as a Novel Molecular Chaperone: Structural and Functional Aspects
Prabhu, S., Raman, B., Ramakrishna, T., & Rao, C. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029810 · Cited by 40
α-Synuclein Aggregates with β-Amyloid or Tau in Human Red Blood Cells: Correlation with Antioxidant Capability and Physical Exercise in Human Healthy Subjects
Daniele, S., Pietrobono, D., Fusi, J., Iofrida, C., Chico, L., Petrozzi, L., Gerfo, A. L., Baldacci, F., Galetta, F., Siciliano, G., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0523-5 · Cited by 41
Heterotypic Amyloid β interactions facilitate amyloid assembly and modify amyloid structure
Konstantoulea, K., Guerreiro, P. S., Ramakers, M., Louros, N. N., Aubrey, L. D., Houben, B., Michiels, E., Vleeschouwer, M. D., Lampi, Y., Ribeiro, L. F., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108591 · Cited by 39
Interactions between Soluble Species of β-Amyloid and α-Synuclein Promote Oligomerization while Inhibiting Fibrillization
Candreva, J., Chau, E., Rice, M. E., & Kim, J. R. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00655 · Cited by 39
Enzymatic degradation of RNA causes widespread protein aggregation in cell and tissue lysates
Aarum, J., Cabrera, C., Jones, T. A., Rajendran, S., Adiutori, R., Giovannoni, G., Barnes, M. R., Malaspina, A., & Sheer, D. (2020) · EMBO Reports · doi:10.15252/embr.201949585 · Cited by 38
Evidence for Prion-Like Mechanisms in Several Neurodegenerative Diseases: Potential Implications for Immunotherapy
Marciniuk, K., Taschuk, R., & Napper, S. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/473706 · Cited by 39

Authors: Mandal, P. K., Pettegrew, J. W., Masliah, E., Hamilton, R. L., & Mandal, R.
Affiliations: University of Pittsburgh Medical Center (US)
University of California San Diego (US)
University of Pittsburgh (US)
Corresponding author: Mandal, Pravat K.
ORCID: Mandal, Pravat K.
Masliah, Eliezer
Hamilton, Ronald L.
Venue: Neurochemical Research
Publisher: Springer Science and Business Media LLC
Published: 2006-09
Volume: 31
Issue: 9
Pages: 1153-1162
ISSN: 0364-3190 (ISSN-L)
1573-6903
DOI: 10.1007/s11064-006-9140-9
OpenAlex: W1965229261
Cited by: 219
References: 48
Citations by year: 2026: 4 · 2025: 10 · 2024: 8 · 2023: 12 · 2022: 12 · 2021: 17 · 2020: 20 · 2019: 17 · 2018: 7 · 2017: 9 · 2016: 9 · 2015: 12 · 2014: 9 · 2013: 11 · 2012: 9
FWCI: 6.34
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Neurochemical Research (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: amyloid-beta, alpha-synuclein, dementia with Lewy bodies, Alzheimer's disease, Parkinson's disease, protein-protein interaction, Aβ40, amyloid-beta 42, amyloid plaques, protein aggregation, molecular pathogenesis
MeSH terms: Alzheimer Disease, Amino Acid Sequence, Brain, Humans, Molecular Sequence Data, Parkinson Disease, Peptide Fragments, Amyloid beta-Peptides, Nuclear Magnetic Resonance, Biomolecular, Lewy Body Disease, alpha-Synuclein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Interaction between Aβ Peptide and α Synuclein: Molecular Mechanisms in Overlapping Pathology of Alzheimer’s and Parkinson’s in Dementia with Lewy Body Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks